TARA
Income statement / Annual
Last year (2023), Protara Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Protara Therapeutics, Inc.'s net income was -$40.42 M.
See Protara Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$2.95 M
|
| Cost of Revenue |
$341,000.00 |
$247,000.00 |
$1.17 M |
$196,000.00 |
$16,000.00 |
$115,000.00 |
$148,000.00 |
$123,000.00 |
$57,000.00 |
$0.00 |
| Gross Profit |
-$341,000.00 |
-$247,000.00 |
-$1.17 M |
-$196,000.00 |
-$16,000.00 |
-$115,000.00 |
-$148,000.00 |
-$123,000.00 |
-$57,000.00 |
$2.95 M |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
| Research and Development
Expenses |
$24.99 M
|
$16.81 M
|
$21.09 M
|
$11.98 M
|
$6.44 M
|
$15.51 M
|
$21.69 M
|
$18.87 M
|
$12.38 M
|
$6.43 M
|
| General & Administrative
Expenses |
$18.62 M
|
$20.74 M
|
$26.40 M
|
$22.46 M
|
$8.82 M
|
$10.57 M
|
$105,989.00
|
$9.84 M
|
$8.49 M
|
$4.10 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$8.42 M
|
-$123,000.00
|
-$57,000.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$18.62 M
|
$20.74 M
|
$26.40 M
|
$22.46 M
|
$8.82 M
|
$10.57 M
|
$8.53 M
|
$9.71 M
|
$8.43 M
|
$4.10 M
|
| Other Expenses |
$0.00 |
$29.52 M |
$0.00 |
$0.00 |
$0.00 |
$207,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$43.61 M |
$37.55 M |
$47.49 M |
$34.44 M |
$15.25 M |
$26.08 M |
$30.21 M |
$28.58 M |
$20.81 M |
$10.53 M |
| Cost And Expenses |
$43.61 M |
$37.55 M |
$47.49 M |
$34.44 M |
$15.25 M |
$26.08 M |
$30.36 M |
$28.71 M |
$20.87 M |
$10.53 M |
| Interest Income |
$2.73 M |
$1.11 M |
$237,000.00 |
$466,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$1.14 M |
$1.74 M |
$34,000.00 |
$0.00 |
$0.00 |
$259,000.00 |
$193,000.00 |
$144,000.00 |
$857,000.00 |
| Depreciation &
Amortization |
$341,000.00
|
$247,000.00
|
$1.17 M
|
$196,000.00
|
$16,000.00
|
$115,000.00
|
$148,000.00
|
$123,000.00
|
$57,000.00
|
$30,000.00
|
| EBITDA |
-$43.27 M
|
-$67.06 M
|
-$46.09 M
|
-$33.78 M
|
-$7.81 M
|
-$20.61 M
|
-$29.82 M
|
-$28.40 M
|
-$21.32 M
|
-$2.45 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
-0.83 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-2.57
|
| Total Other
Income/Expenses Net |
$3.19 M
|
$1.11 M
|
$237,000.00
|
$466,000.00
|
$7.42 M
|
$17.13 M
|
$398,000.00
|
$179,000.00
|
-$507,000.00
|
$4.24 M
|
| Income Before Tax |
-$40.42 M |
-$65.95 M |
-$47.25 M |
-$33.98 M |
-$14.99 M |
-$25.44 M |
-$29.96 M |
-$28.53 M |
-$21.38 M |
-$3.34 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-1.13
|
| Income Tax Expense |
$0.00 |
-$1.14 M |
-$117,000.00 |
-$466,000.00 |
-$262,000.00 |
$5.35 M |
$657,000.00 |
$372,000.00 |
-$363,000.00 |
$5.10 M |
| Net Income |
-$40.42 M |
-$64.82 M |
-$47.14 M |
-$33.51 M |
-$14.73 M |
-$25.44 M |
-$29.96 M |
-$28.53 M |
-$21.38 M |
-$3.34 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
-1.13 |
| EPS |
-3.57 |
-5.76 |
-4.2 |
-4.63 |
-228.6 |
-9.93 |
-69.38 |
-68.9 |
-51.94 |
-43.62 |
| EPS Diluted |
-3.57 |
-5.76 |
-4.2 |
-4.63 |
-228.6 |
-9.93 |
-69.38 |
-68.9 |
-51.94 |
-43.62 |
| Weighted Average Shares
Out |
$11.33 M
|
$11.26 M
|
$11.23 M
|
$7.23 M
|
$64,437.00
|
$2.56 M
|
$431,858.00
|
$414,044.00
|
$411,603.00
|
$76,610.00
|
| Weighted Average Shares
Out Diluted |
$11.33 M
|
$11.26 M
|
$11.23 M
|
$7.23 M
|
$64,437.00
|
$2.56 M
|
$431,858.00
|
$414,044.00
|
$411,603.00
|
$76,610.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
